Previous 10 | Next 10 |
Gainers: CRWD +7.3% . MCHP +6.3% . CAKE +5.5% . AMSC +3.1% . LYFT +3.1% . More news on: CrowdStrike Holdings, Inc., Microchip Technology Incorporated, The Cheesecake Factory Incorporated, Stocks on the move, , Read more ...
GERMANTOWN, Md. , May 15, 2020 /PRNewswire/ -- Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced preclinical data for its innovative investigational PRGN-3005 Ultr...
The following slide deck was published by Precigen, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Image source: The Motley Fool. Precigen, Inc. (NASDAQ: PGEN) Q1 2020 Earnings Call May 6, 2020 , 4:15 p.m. ET Operator Continue reading
Precigen, Inc. (PGEN) Q1 2020 Earnings Conference Call May 06, 2020, 16:15 ET Company Participants Steven Harasym - VP, IR Helen Sabzevari - President & CEO Tom Samuelson - VP Conference Call Participants Jason Butler - JMP Securities Swayampakula Ramakanth - H.C. Wa...
Precigen (NASDAQ: PGEN ): Q1 GAAP EPS of -$0.19 beats by $0.05 . Revenue of $29.8M (+31.9% Y/Y) beats by $17.8M . Press Release More news on: Precigen, Inc., Earnings news and commentary, Healthcare stocks news,
GERMANTOWN, Md. , May 6, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter financial results for 2020. ...
GERMANTOWN, Md. , April 29, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release first quarter 2020 financial results after th...
Biofrontera Inks New Licensing Deal, Reports FY 2019 Numbers Biofrontera AG ( BFRA ) announced inking a new exclusive licensing deal with Maruho Co. Ltd. of Osaka, Japan. The deal pertains to the development and commercialization of Ameluz in East Asia and Oceania. Under the terms of the c...
The FDA has signed off on Precigen's (NASDAQ: PGEN ) IND for a Phase 1/2 clinical trial evaluating PRGN-2009, an off-the-shelf immunotherapy based on its AdenoVerse platform, in patients with human papillomavirus (HPV)-positive solid tumors. More news on: Precigen, Inc., Healthcare stock...
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...